Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations

被引：17

作者：

Langrand-Escure, J. ^{[1
]}

de Crevoisier, R. ^{[2
,3
]}

Llagostera, C. ^{[4
]}

Crehange, G. ^{[5
]}

Delaroche, G. ^{[1
]}

Lafond, C. ^{[2
,3
]}

Bonin, C. ^{[6
]}

Bideault, F. ^{[5
]}

Sargos, P. ^{[7
]}

Belhomme, S. ^{[7
]}

Pasquier, D. ^{[8
]}

Latorzeff, I ^{[9
]}

Supiot, S. ^{[4
]}

Hennequin, C. ^{[10
]}

机构：

[1] Inst Cancerol La Loire Lucien Neuwirth, 180 Bis,Ave Albert Raimond, F-42270 St Priest En Jarez, France

[2] Ctr Eugene Marquis, Dept Radiotherapie, Ave Bataille Flandres Dunkerque, F-35042 Rennes, France

[3] Inserm 1099, LTSI, 263 Ave Gen Leclerc, F-35042 Rennes, France

[4] Inst cancerol Ouest Rene Gauducheau, Blvd Jacques Monod, F-44805 St Herblain, France

[5] Ctr Georges Francois Leclerc, Dept Radiotherapie, 1 Ave Prof Marion, F-21000 Dijon, France

[6] CHU Jean Minjoz, Serv Radiotherapie, 3 Blvd Alexandre Fleming, F-25000 Besancon, France

[7] Inst Bergonie, Dept Radiotherapie, 229 Cours Argonne, F-33000 Bordeaux, France

[8] Ctr Oscar Lambret, Dept Radiotherapie, 3 Rue Frederic Combemale, F-59020 Lille, France

[9] Clin Pasteur, Dept Oncol Radiotherapie, Bat Atrium,1 Rue Petite Vitesse, F-31300 Toulouse, France

[10] Hop St Louis, Serv Cancerol Radiotherapie, 1 Ave Claude Vellefaux, F-75010 Paris, France

来源：

CANCER RADIOTHERAPIE | 2018年 / 22卷 / 02期

关键词：

Prostate cancer; Hypofractionation; Radiotherapy; Image-guided radiation therapy; Recommendations; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; III RANDOMIZED-TRIAL; RADIATION-THERAPY; NON-INFERIORITY; PHASE-3; TRIAL; ACUTE TOXICITY; HIGH-RISK; ADENOCARCINOMA;

D O I：

10.1016/j.canrad.2017.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques. (C) 2018 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).

引用

页码：193 / 198

页数：6

共 50 条

[11] Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: The Triumph of Radiobiology
Kougioumtzopoulou, Andromachi
Platoni, Kalliopi
Zygogianni, Anna
Kounadis, George
Syrigos, Konstantinos N.
Psyrri, Adamantia
Bamias, Aristotelis
Kelekis, Nikolaos
Kouloulias, Vasileios
REVIEWS ON RECENT CLINICAL TRIALS, 2021, 16 (04) : 351 - 371
[12] EORTC, GENITO URINARY GROUP TRIALS FOR CANCER OF THE PROSTATE (1986)
BOLLACK, C
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (08): : 1233 - 1233
[13] Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers
Krengli, Marco
Pisani, Carla
Deantonio, Letizia
Surico, Daniela
Volpe, Alessandro
Surico, Nicola
Terrone, Carlo
Radiation Oncology, 2017, 12
[14] Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers
Marco Krengli
Carla Pisani
Letizia Deantonio
Daniela Surico
Alessandro Volpe
Nicola Surico
Carlo Terrone
Radiation Oncology, 12
[15] The EORTC Genito-Urinary Tract Cancer Group: 25 years of achievements and future strategies
Bono, A
Zurlo, A
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S71 - S74
[16] Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
Flechon, A.
Pouessel, D.
Ferlay, C.
Perol, D.
Beuzeboc, P.
Gravis, G.
Joly, F.
Oudard, S.
Deplanque, G.
Zanetta, S.
Fargeot, P.
Priou, F.
Droz, J. P.
Culine, S.
ANNALS OF ONCOLOGY, 2011, 22 (11) : 2476 - 2481
[17] Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial
Koper, PC
Jansen, P
van Putten, W
van Os, M
Wijnmaalen, AJ
Lebesque, JV
Levendag, PC
RADIOTHERAPY AND ONCOLOGY, 2004, 73 (01) : 1 - 9
[18] Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma
Hayden, A. J.
Martin, J. M.
Kneebone, A. B.
Lehman, M.
Wiltshire, K. L.
Skala, M.
Christie, D.
Vial, P.
McDowall, R.
Tai, K-H
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2010, 54 (06) : 513 - 525
[19] In silico identification of dose equivalences in hypofractionated prostate cancer radiotherapy
Sosa-Marrero, C.
Briens, A.
Fontaine, P.
Acosta, O.
de Crevoisier, R.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1878 - S1879
[20] Improved Outcomes With Dose Escalated Hypofractionated Radiotherapy for Prostate Cancer
Mackenzie, J.
Law, A. B.
Kerr, G. R.
Higgins, G. S.
Howard, G. C. W.
Malik, J. M.
McLaren, D. B.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S495 - S495

← 1 2 3 4 5 →